Improving the evaluation of new cancer treatments: challenges and opportunities.
about
Predictive biomarkers for treatment selection: statistical considerationsA composite model for subgroup identification and prediction via bicluster analysisAnticancer drug development incorporating high-content screening and RNAi: synergistic approaches to improve target identification and validation.Pharmacologic down-regulation of EZH2 suppresses bladder cancer in vitro and in vivo.Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma.Drug development in oncology: classical cytotoxics and molecularly targeted agents.Subgroup identification for treatment selection in biomarker adaptive designChallenges in clinical studies with multiple imaging probes.Individualised cancer therapeutics: dream or reality? Therapeutics construction.A methodologic analysis of chemoprevention and cancer prevention strategies for gastrointestinal cancer.Metastasis: recent discoveries and novel treatment strategies.Human xenografts are not rejected in a naturally occurring immunodeficient porcine line: a human tumor model in pigs.A large animal model to evaluate the effects of Hsp90 inhibitors for the treatment of lung adenocarcinoma.Developing and validating continuous genomic signatures in randomized clinical trials for predictive medicine.Boswellic acids: a group of medicinally important compounds.Molecular Imaging of Proteases in Cancer.Monoclonal antibodies in the treatment of multiple myeloma.A visualization method measuring the performance of biomarkers for guiding treatment decisions.Differential network analysis for the identification of condition-specific pathway activity and regulation.Adenoviral vectors expressing human endostatin-angiostatin and soluble Tie2: enhanced suppression of tumor growth and antiangiogenic effects in a prostate tumor model.pH-Driven preparation of two related platinum(ii) complexes exhibiting distinct cytotoxic properties.Small molecule inhibitors of tyrosine kinase: waiting for the good news in colorectal cancer as well.Nanoparticle core stability and surface functionalization drive the mTOR signaling pathway in hepatocellular cell lines.Marketing Authorization Procedures for Advanced Cancer Drugs: Exploring the Views of Patients, Oncologists, Healthcare Decision Makers, and Citizens in France.Acid-Labile Acyclic Cucurbit[n]uril Molecular Containers for Controlled Release.Neoadjuvant Treatment Approach: The Rosetta Stone for Breast Cancer?Targeted therapies for patients with germ cell tumors
P2860
Q26778367-C066CB60-1EBA-45A6-9F99-8CB8A3599077Q34408139-E90D9EB3-B4DF-44E6-84BA-C0690C2C8271Q34626275-5A699677-E77C-41F1-AF17-845B8EB15E8AQ34786445-87094CAB-AB22-4FF6-9D25-3F09526561C1Q35821594-E7D9AC53-7C8B-4876-A2C5-36631C165378Q35827606-50D399A1-DB36-44FF-99F1-E6B01EE8C1ABQ35863520-92834F06-E7CB-4632-B2D7-A33BB519DD32Q36177540-87601C43-6E48-426E-998F-C23F2837F9E2Q36299931-4EB15784-5F48-4556-BCBE-DA35A16F5958Q36386030-7E2FA0B7-0F04-4CEF-ADF1-6D69363CDB04Q36407511-E90DFE0C-BF83-4255-82F1-7DF2EEBFE4F6Q36574540-7BFBBDA7-B7F5-4772-9040-C968C3DE4424Q36593621-3D5EEEF0-6C32-44CA-9A10-4D8D176D1ACDQ37096663-3F8DC745-A3AF-463A-AB39-9F374D8E4242Q37448772-F4A2D0BD-2480-48FE-838F-77F5FB234FF6Q37710417-D7B9B4C8-F114-479C-BF9C-38810D9B3A66Q37903377-A5FB836A-5D1F-4190-823B-5DA3E3C72BF2Q38935953-49EE974F-A0D1-4481-AC2B-2BD2C02FD322Q39141925-1BB9A2B9-03D5-485C-859A-A1AA495BD159Q40372092-9C5DE4D8-5926-48D4-9913-698B2AEE1E6EQ46323059-6E18BF78-42A9-4603-BB37-3EFAC3D7E90CQ46581102-8CB6634D-3A41-4A5B-9B00-5B28176E8160Q47124020-9D54FE1A-E34C-40A9-96F6-B7C39FA017F3Q47989250-743C4E6B-8037-4E0A-9BF6-BA914BE5A0EFQ48232837-F639A4CF-4840-47C9-BD11-822729483A41Q53838654-1868F24F-E416-4BCF-8B1C-5F293AD80448Q57837665-3A0B54F0-E725-4CE7-A36D-CA93899C0F46
P2860
Improving the evaluation of new cancer treatments: challenges and opportunities.
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Improving the evaluation of new cancer treatments: challenges and opportunities.
@ast
Improving the evaluation of new cancer treatments: challenges and opportunities.
@en
type
label
Improving the evaluation of new cancer treatments: challenges and opportunities.
@ast
Improving the evaluation of new cancer treatments: challenges and opportunities.
@en
prefLabel
Improving the evaluation of new cancer treatments: challenges and opportunities.
@ast
Improving the evaluation of new cancer treatments: challenges and opportunities.
@en
P2093
P356
P1476
Improving the evaluation of new cancer treatments: challenges and opportunities.
@en
P2093
David H Johnson
David P Carbone
Mace L Rothenberg
P2888
P304
P356
10.1038/NRC1047
P407
P577
2003-04-01T00:00:00Z